Topical Dutasteride Compositions for Diverse Skin Health Applications

Publication ID: 24-11857556_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Topical Dutasteride Compositions for Diverse Skin Health Applications,” Published Technical Disclosure No. 24-11857556_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857556_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,556.

Summary of the Inventive Concept

The present inventive concept relates to the application of topical dutasteride compositions in various skin health areas, including skin aging, acne scars, wound healing, skin elasticity, and rosacea treatment, leveraging the 5α-reductase inhibitory effects of dutasteride.

Background and Problem Solved

The original patent disclosed topical compositions of dutasteride for preventing hair loss and stimulating hair growth. However, the potential benefits of dutasteride in other skin health areas were not explored. The present inventive concept addresses this limitation by applying the core technology to novel applications, providing a comprehensive solution for diverse skin health concerns.

Detailed Description of the Inventive Concept

The new inventive concept encompasses various topical compositions containing dutasteride, which inhibit 5α-reductase activity, thereby reducing inflammation, promoting collagen production, and improving skin elasticity. The compositions can be formulated as creams, gels, or ointments and may include additional ingredients to enhance their efficacy. In the context of skin aging, the composition reduces wrinkles and fine lines. For acne scars, the composition promotes collagen production and reduces inflammation. In wound healing, the composition promotes tissue regeneration and reduces scarring. The composition can also be used to improve skin elasticity, reducing skin sagging and improving skin firmness. Furthermore, the composition can be used to treat rosacea, reducing redness and inflammation.

Novelty and Inventive Step

The new claims are novel and non-obvious as they apply the core technology of the original patent to entirely new applications and use cases, demonstrating an inventive step beyond the original patent's scope.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include varying the concentration of dutasteride, combining it with other active ingredients, or using different formulations to enhance efficacy. Additionally, the composition could be used in conjunction with other therapies or devices to enhance its effects.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the skincare and pharmaceutical industries, targeting a wide range of skin health concerns. The market for skincare products is growing rapidly, and the inventive concept's diverse applications position it for significant market share.

Field of Art

Pharmaceutical and cosmetic formulations, specifically topical compositions for dermatological applications involving 5α-reductase inhibitors and skin treatment technologies

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist or dermatological researcher with expertise in drug delivery systems, topical formulations, and understanding of enzyme inhibition mechanisms, holding at least a master's degree with practical experience in developing skin-related therapeutic compositions

Obviousness Rationale

A PHOSITA would recognize that the fundamental mechanism of dutasteride's 5α-reductase inhibition disclosed in the source patent naturally suggests broader applications beyond hair loss treatment. The molecular properties and anti-inflammatory characteristics of dutasteride inherently imply potential for diverse skin health interventions. Given the known biological effects of 5α-reductase inhibition, extending the composition to address skin aging, wound healing, and inflammatory conditions represents a logical and predictable technological progression.

Obvious Combinations & Variations

Source Patent Element
Topical composition containing 0.056 wt% dutasteride with medium chain triglycerides and ethanol
PTD Variation
Applying the same composition to treat skin aging and reduce wrinkles
Obviousness Reasoning
Known anti-inflammatory properties and established topical delivery mechanism make skin aging treatment a predictable extension of existing technology
Source Patent Element
5α-reductase inhibition mechanism for hair growth
PTD Variation
Utilizing the same mechanism to promote collagen production and wound healing
Obviousness Reasoning
Enzyme inhibition's systemic effects are well-understood, and applying this to tissue regeneration represents a routine scientific extrapolation
Source Patent Element
Dutasteride-based topical formulation targeting hormonal processes
PTD Variation
Expanding application to rosacea treatment by addressing inflammatory pathways
Obviousness Reasoning
Inflammatory condition treatment is a natural progression given the known anti-inflammatory characteristics of 5α-reductase inhibitors
Source Patent Element
Composition with defined carrier substances like medium chain triglycerides
PTD Variation
Modifying carrier substances to optimize absorption for different skin conditions
Obviousness Reasoning
Formulation optimization is a standard practice in pharmaceutical development, representing an obvious design choice for a skilled practitioner
35 U.S.C. § 103 Summary: Based on US Patent 11857556's disclosure of topical dutasteride compositions, the present publication demonstrates that a person of ordinary skill in the art would find the expanded applications of 5α-reductase inhibition for diverse skin health interventions to be obvious and predictable. The technical variations represent routine scientific exploration of an established pharmaceutical mechanism, thereby rendering potential claims to such applications unpatentable under standard obviousness criteria.

Original Patent Information

Patent NumberUS 11,857,556
TitleTopical compositions of dutasteride
Assignee(s)SHILPA MEDICARE LIMITED